Geode Capital Management, LLC Cue Biopharma, Inc. Transaction History

Geode Capital Management, LLC

  • $1.24 Trillion
  • Q1 2025

A detailed history of Geode Capital Management, LLC transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 693,890 shares of CUE stock, worth $513,478. This represents 0.0% of its overall portfolio holdings.

Number of Shares
693,890
Previous 631,281 9.92%
Holding current value
$513,478
Previous $650,000 2.92%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 13, 2025
BUY
$0.91 - $1.75 $56,974 - $109,565
62,609 Added 9.92%
693,890 $631,000
Q4 2024

Feb 12, 2025
BUY
$0.71 - $1.88 $86,942 - $230,213
122,454 Added 24.07%
631,281 $650,000
Q3 2024

Nov 12, 2024
BUY
$0.45 - $1.08 $7,366 - $17,680
16,371 Added 3.32%
508,827 $386,000
Q2 2024

Aug 09, 2024
SELL
$1.24 - $2.18 $429,133 - $754,443
-346,075 Reduced 41.27%
492,456 $610,000
Q1 2024

May 13, 2024
BUY
$1.77 - $3.09 $44,685 - $78,010
25,246 Added 3.1%
838,531 $1.58 Million
Q4 2023

Feb 13, 2024
BUY
$1.72 - $3.1 $87,486 - $157,678
50,864 Added 6.67%
813,285 $2.15 Million
Q3 2023

Nov 13, 2023
BUY
$2.23 - $4.69 $73,536 - $154,657
32,976 Added 4.52%
762,421 $1.75 Million
Q2 2023

Aug 11, 2023
BUY
$3.11 - $4.91 $860,465 - $1.36 Million
276,677 Added 61.11%
729,445 $2.66 Million
Q1 2023

May 15, 2023
BUY
$2.41 - $3.74 $330,027 - $512,159
136,941 Added 43.36%
452,768 $1.62 Million
Q4 2022

Feb 13, 2023
BUY
$2.39 - $3.95 $41,158 - $68,022
17,221 Added 5.77%
315,827 $900,000
Q3 2022

Nov 14, 2022
BUY
$2.23 - $3.37 $1,190 - $1,799
534 Added 0.18%
298,606 $665,000
Q2 2022

Aug 12, 2022
SELL
$2.49 - $5.92 $623,329 - $1.48 Million
-250,333 Reduced 45.65%
298,072 $742,000
Q1 2022

May 13, 2022
BUY
$4.41 - $12.28 $119,074 - $331,572
27,001 Added 5.18%
548,405 $2.68 Million
Q4 2021

Feb 11, 2022
SELL
$10.86 - $17.85 $879,746 - $1.45 Million
-81,008 Reduced 13.45%
521,404 $5.9 Million
Q3 2021

Nov 12, 2021
BUY
$10.06 - $15.3 $866,095 - $1.32 Million
86,093 Added 16.67%
602,412 $8.78 Million
Q2 2021

Aug 13, 2021
BUY
$10.9 - $14.53 $329,943 - $439,823
30,270 Added 6.23%
516,319 $6.02 Million
Q1 2021

May 12, 2021
BUY
$11.2 - $16.09 $620,323 - $891,160
55,386 Added 12.86%
486,049 $5.93 Million
Q4 2020

Feb 12, 2021
BUY
$11.12 - $16.4 $434,302 - $640,518
39,056 Added 9.97%
430,663 $5.39 Million
Q3 2020

Nov 13, 2020
BUY
$15.05 - $23.54 $216,253 - $338,246
14,369 Added 3.81%
391,607 $5.89 Million
Q2 2020

Aug 13, 2020
BUY
$12.7 - $30.73 $871,867 - $2.11 Million
68,651 Added 22.25%
377,238 $9.25 Million
Q1 2020

May 14, 2020
BUY
$9.85 - $22.27 $447,002 - $1.01 Million
45,381 Added 17.24%
308,587 $4.38 Million
Q4 2019

Feb 13, 2020
BUY
$7.06 - $17.47 $370,452 - $916,685
52,472 Added 24.9%
263,206 $4.18 Million
Q3 2019

Nov 12, 2019
BUY
$6.78 - $9.28 $38,008 - $52,023
5,606 Added 2.73%
210,734 $1.78 Million
Q2 2019

Aug 14, 2019
BUY
$7.18 - $9.65 $423,210 - $568,799
58,943 Added 40.32%
205,128 $1.84 Million
Q1 2019

May 14, 2019
BUY
$4.7 - $9.29 $71,552 - $141,430
15,224 Added 11.62%
146,185 $1.13 Million
Q4 2018

Feb 13, 2019
BUY
$4.35 - $8.73 $64,915 - $130,277
14,923 Added 12.86%
130,961 $615,000
Q3 2018

Nov 13, 2018
BUY
$7.91 - $11.89 $50,014 - $75,180
6,323 Added 5.76%
116,038 $1.05 Million
Q2 2018

Aug 14, 2018
BUY
$10.93 - $14.48 $420,597 - $557,204
38,481 Added 54.02%
109,715 $1.3 Million
Q1 2018

May 15, 2018
BUY
$11.63 - $17.25 $828,451 - $1.23 Million
71,234 New
71,234 $1 Million

Others Institutions Holding CUE

# of Institutions
52
Shares Held
11.5M
Call Options Held
10.1K
Put Options Held
1.4K
View Full List

About Cue Biopharma, Inc.

CUE Quotes by TradingView
  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $26.2M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email